Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition Disorders | 8 | 2010 | 67 | 1.150 |
Why?
|
| Diet | 11 | 2018 | 21 | 0.860 |
Why?
|
| Dementia | 3 | 2014 | 32 | 0.770 |
Why?
|
| Alzheimer Disease | 7 | 2014 | 91 | 0.730 |
Why?
|
| Humans | 36 | 2018 | 2210 | 0.730 |
Why?
|
| Dietary Fats | 4 | 2014 | 7 | 0.580 |
Why?
|
| Female | 28 | 2018 | 1137 | 0.580 |
Why?
|
| Folic Acid | 5 | 2009 | 6 | 0.530 |
Why?
|
| Male | 25 | 2017 | 1214 | 0.530 |
Why?
|
| Trans Fatty Acids | 2 | 2014 | 2 | 0.510 |
Why?
|
| Fatty Acids | 2 | 2014 | 3 | 0.510 |
Why?
|
| Dietary Supplements | 5 | 2011 | 8 | 0.510 |
Why?
|
| Aged | 18 | 2014 | 490 | 0.460 |
Why?
|
| Blood Viscosity | 4 | 2003 | 5 | 0.460 |
Why?
|
| Hypertriglyceridemia | 3 | 2010 | 3 | 0.460 |
Why?
|
| Hypercholesterolemia | 5 | 2005 | 6 | 0.430 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 44 | 0.410 |
Why?
|
| Middle Aged | 15 | 2018 | 608 | 0.400 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2005 | 7 | 0.390 |
Why?
|
| Folic Acid Deficiency | 2 | 2009 | 2 | 0.370 |
Why?
|
| Vitamins | 1 | 2011 | 3 | 0.360 |
Why?
|
| Diet, Mediterranean | 1 | 2010 | 5 | 0.350 |
Why?
|
| Fenofibrate | 1 | 2010 | 1 | 0.350 |
Why?
|
| Lipoproteins | 1 | 2010 | 2 | 0.350 |
Why?
|
| Postprandial Period | 1 | 2010 | 2 | 0.350 |
Why?
|
| Hypolipidemic Agents | 1 | 2010 | 2 | 0.350 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 3 | 0.350 |
Why?
|
| Vitamin B Complex | 2 | 2011 | 2 | 0.350 |
Why?
|
| Vitamin E | 6 | 2011 | 7 | 0.340 |
Why?
|
| Feeding Behavior | 5 | 2017 | 12 | 0.340 |
Why?
|
| Homocysteine | 2 | 2007 | 3 | 0.330 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2009 | 1 | 0.310 |
Why?
|
| Triglycerides | 3 | 2010 | 7 | 0.290 |
Why?
|
| Lipoproteins, LDL | 2 | 2005 | 2 | 0.280 |
Why?
|
| Hyperhomocysteinemia | 1 | 2006 | 2 | 0.260 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 5 | 0.260 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 235 | 0.260 |
Why?
|
| Apolipoprotein E4 | 3 | 2016 | 26 | 0.250 |
Why?
|
| Coronary Disease | 2 | 2002 | 5 | 0.240 |
Why?
|
| Adult | 11 | 2018 | 681 | 0.230 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2004 | 1 | 0.220 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2004 | 4 | 0.220 |
Why?
|
| Vitamin B 12 | 3 | 2009 | 5 | 0.200 |
Why?
|
| Surveys and Questionnaires | 7 | 2016 | 102 | 0.200 |
Why?
|
| Arteriosclerosis | 2 | 2004 | 3 | 0.190 |
Why?
|
| Cohort Studies | 5 | 2010 | 143 | 0.190 |
Why?
|
| Fibrinogen | 3 | 2002 | 5 | 0.190 |
Why?
|
| Cholesterol | 4 | 2014 | 10 | 0.190 |
Why?
|
| Seafood | 2 | 2016 | 3 | 0.180 |
Why?
|
| Anticholesteremic Agents | 2 | 1999 | 2 | 0.170 |
Why?
|
| Risk Factors | 5 | 2009 | 153 | 0.160 |
Why?
|
| Double-Blind Method | 4 | 2010 | 37 | 0.160 |
Why?
|
| Simvastatin | 4 | 2005 | 5 | 0.160 |
Why?
|
| Longitudinal Studies | 5 | 2016 | 88 | 0.160 |
Why?
|
| Nutritional Status | 2 | 2011 | 4 | 0.160 |
Why?
|
| Pravastatin | 5 | 2005 | 5 | 0.160 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2016 | 3 | 0.160 |
Why?
|
| Antioxidants | 3 | 2005 | 10 | 0.160 |
Why?
|
| Nutrition Policy | 2 | 2010 | 2 | 0.150 |
Why?
|
| Chicago | 5 | 2017 | 65 | 0.150 |
Why?
|
| Cholesterol, LDL | 2 | 2010 | 4 | 0.150 |
Why?
|
| Hypertension | 1 | 2018 | 11 | 0.140 |
Why?
|
| Health Promotion | 1 | 2018 | 13 | 0.140 |
Why?
|
| Exercise | 1 | 2018 | 19 | 0.140 |
Why?
|
| Telemedicine | 1 | 2018 | 7 | 0.140 |
Why?
|
| Risk | 3 | 2014 | 25 | 0.140 |
Why?
|
| Nutritive Value | 1 | 2017 | 1 | 0.140 |
Why?
|
| Food | 1 | 2017 | 2 | 0.140 |
Why?
|
| Choice Behavior | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 54 | 0.120 |
Why?
|
| Brain | 2 | 2014 | 92 | 0.120 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2014 | 1 | 0.110 |
Why?
|
| Blood-Brain Barrier | 1 | 2014 | 6 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 62 | 0.110 |
Why?
|
| Peritoneal Dialysis | 1 | 2014 | 1 | 0.110 |
Why?
|
| Nutrition Therapy | 1 | 2014 | 1 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2014 | 2 | 0.110 |
Why?
|
| Animals | 2 | 2014 | 734 | 0.110 |
Why?
|
| Docosahexaenoic Acids | 2 | 2011 | 2 | 0.100 |
Why?
|
| Cognition | 2 | 2005 | 79 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 1 | 1992 | 3 | 0.100 |
Why?
|
| Indicators and Reagents | 2 | 2009 | 4 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 69 | 0.090 |
Why?
|
| Epidemiologic Studies | 1 | 2011 | 4 | 0.090 |
Why?
|
| Biomarkers | 2 | 2009 | 51 | 0.090 |
Why?
|
| Research Design | 1 | 2011 | 19 | 0.090 |
Why?
|
| Wine | 1 | 2010 | 1 | 0.090 |
Why?
|
| Cholesterol, VLDL | 1 | 2010 | 1 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 4 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2010 | 8 | 0.090 |
Why?
|
| Placebos | 1 | 2010 | 7 | 0.090 |
Why?
|
| Memory | 1 | 2010 | 20 | 0.090 |
Why?
|
| Ascorbic Acid | 2 | 2002 | 13 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2014 | 137 | 0.080 |
Why?
|
| Blood Chemical Analysis | 2 | 2006 | 4 | 0.080 |
Why?
|
| Age Factors | 4 | 2018 | 61 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2006 | 69 | 0.080 |
Why?
|
| Methylmalonic Acid | 1 | 2009 | 1 | 0.080 |
Why?
|
| Energy Intake | 3 | 2017 | 8 | 0.080 |
Why?
|
| Neuropsychological Tests | 4 | 2016 | 112 | 0.080 |
Why?
|
| Carotenoids | 2 | 2002 | 2 | 0.070 |
Why?
|
| Chromatography | 1 | 1988 | 1 | 0.070 |
Why?
|
| Contraceptives, Oral | 2 | 1978 | 2 | 0.070 |
Why?
|
| Diet Surveys | 2 | 2006 | 2 | 0.070 |
Why?
|
| Food Analysis | 1 | 2007 | 1 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2006 | 4 | 0.070 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 1 | 0.060 |
Why?
|
| Copper | 1 | 2006 | 6 | 0.060 |
Why?
|
| Fruit | 2 | 2017 | 2 | 0.060 |
Why?
|
| Vegetables | 2 | 2017 | 2 | 0.060 |
Why?
|
| Beverages | 2 | 2017 | 3 | 0.060 |
Why?
|
| Fish Products | 1 | 2005 | 1 | 0.060 |
Why?
|
| Fishes | 1 | 2005 | 1 | 0.060 |
Why?
|
| Food, Fortified | 1 | 2005 | 2 | 0.060 |
Why?
|
| Bone Remodeling | 1 | 2005 | 28 | 0.060 |
Why?
|
| Tocopherols | 1 | 2005 | 1 | 0.060 |
Why?
|
| Young Adult | 2 | 2018 | 209 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2005 | 7 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 133 | 0.060 |
Why?
|
| Hyperlipoproteinemias | 1 | 2004 | 1 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 1 | 0.060 |
Why?
|
| Nutrition Disorders | 1 | 2003 | 1 | 0.050 |
Why?
|
| Drinking | 1 | 2003 | 1 | 0.050 |
Why?
|
| Hemorheology | 1 | 2003 | 1 | 0.050 |
Why?
|
| Sex Factors | 2 | 2018 | 48 | 0.050 |
Why?
|
| Lipids | 2 | 2005 | 9 | 0.050 |
Why?
|
| Vitamin A | 1 | 2002 | 1 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2002 | 4 | 0.050 |
Why?
|
| Probability | 1 | 2002 | 9 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2002 | 18 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 53 | 0.050 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 1978 | 2 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 5 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2001 | 22 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2001 | 6 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2001 | 22 | 0.040 |
Why?
|
| Adolescent | 2 | 2018 | 218 | 0.040 |
Why?
|
| Nutrition Assessment | 3 | 2005 | 4 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 1999 | 2 | 0.040 |
Why?
|
| Cytokines | 1 | 1999 | 18 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1998 | 1 | 0.040 |
Why?
|
| Postmenopause | 1 | 1998 | 4 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 1998 | 29 | 0.040 |
Why?
|
| Life Style | 1 | 2018 | 5 | 0.040 |
Why?
|
| Internet | 1 | 2018 | 10 | 0.040 |
Why?
|
| Health Behavior | 1 | 2018 | 11 | 0.040 |
Why?
|
| Contraceptive Agents, Female | 1 | 1977 | 1 | 0.030 |
Why?
|
| Mestranol | 1 | 1977 | 1 | 0.030 |
Why?
|
| Norethindrone | 1 | 1977 | 1 | 0.030 |
Why?
|
| Blood | 1 | 1977 | 3 | 0.030 |
Why?
|
| Research | 1 | 1977 | 6 | 0.030 |
Why?
|
| Diet Records | 1 | 2017 | 1 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2017 | 2 | 0.030 |
Why?
|
| Lovastatin | 1 | 1996 | 1 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 1996 | 3 | 0.030 |
Why?
|
| Neuroprotection | 1 | 2016 | 1 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 2 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 5 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 19 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 22 | 0.030 |
Why?
|
| Incidence | 2 | 2006 | 62 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 61 | 0.030 |
Why?
|
| Dietary Fiber | 1 | 2014 | 1 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2005 | 21 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2014 | 56 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 1992 | 17 | 0.020 |
Why?
|
| beta Carotene | 2 | 2002 | 2 | 0.020 |
Why?
|
| Chemistry | 1 | 1988 | 1 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1988 | 1 | 0.020 |
Why?
|
| Dehydroascorbic Acid | 1 | 1988 | 1 | 0.020 |
Why?
|
| Drug Stability | 1 | 1988 | 1 | 0.020 |
Why?
|
| 2,3-Diketogulonic Acid | 1 | 1988 | 1 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1988 | 2 | 0.020 |
Why?
|
| Eating | 1 | 2005 | 3 | 0.020 |
Why?
|
| Aging | 1 | 2006 | 77 | 0.020 |
Why?
|
| Educational Status | 1 | 2005 | 23 | 0.020 |
Why?
|
| Motor Activity | 1 | 2005 | 21 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2005 | 7 | 0.020 |
Why?
|
| Collagen | 1 | 2005 | 21 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2005 | 10 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 6 | 0.010 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 1 | 0.010 |
Why?
|
| gamma-Tocopherol | 1 | 2005 | 1 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 7 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2005 | 4 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 9 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 29 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 1 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2004 | 1 | 0.010 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2004 | 1 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2003 | 1 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 2 | 0.010 |
Why?
|
| Hematocrit | 1 | 2003 | 1 | 0.010 |
Why?
|
| Elasticity | 1 | 2003 | 12 | 0.010 |
Why?
|
| Fasting | 1 | 2003 | 2 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 21 | 0.010 |
Why?
|
| Fluid Therapy | 1 | 2003 | 12 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2002 | 3 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2002 | 4 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2002 | 7 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2002 | 6 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2002 | 13 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 159 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 1999 | 1 | 0.010 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1999 | 1 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1999 | 4 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1999 | 8 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 22 | 0.010 |
Why?
|
| Medroxyprogesterone | 1 | 1998 | 1 | 0.010 |
Why?
|
| Estradiol | 1 | 1998 | 3 | 0.010 |
Why?
|
| Hemolysis | 1 | 1978 | 1 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1978 | 1 | 0.010 |
Why?
|
| Biology | 1 | 1977 | 1 | 0.010 |
Why?
|
| Contraception | 1 | 1977 | 1 | 0.010 |
Why?
|
| Contraceptive Agents | 1 | 1977 | 1 | 0.010 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1977 | 1 | 0.010 |
Why?
|
| Family Planning Services | 1 | 1977 | 1 | 0.010 |
Why?
|
| Norethynodrel | 1 | 1977 | 1 | 0.010 |
Why?
|
| Physiology | 1 | 1977 | 2 | 0.010 |
Why?
|
| Smoking | 1 | 1992 | 28 | 0.010 |
Why?
|